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Introduction 
Budd-Chiari syndrome (BCS) is a rare condition. It 
results from occlusion of hepatic venous outflow. 
Abdominal pain, ascites, and liver enlargement are 
classic triad symptoms in BCS. Myeloproliferative 
disorders, thrombophilias, malignancy, and infections 
are common etiological factors for BCS.1It can be due 
to thrombotic or nonthrombotic obstruction of hepatic 
venous outflow. It was first described by Budd in 
1845 and subsequently by Chiari in 1899.2,3 Site of 
hepatic outflow obstruction in BCS is variable. It is 
frequently noted at level of inferior vena cava (IVC) 
and hepatic veins. Untreated patients with BCS have 
poor prognosis. Death occurs due to progressive liver 
failure in three months to three years after the 
diagnosis is made.4 With shunt procedures and liver 
transplantation, 5 year survival is up to 87%.5,6,7 Here 
we describe a patient with BCS, who was diagnosed at 
our Medical Unit. Etiology of BCS could not be made. 
Patient was managed conservatively as he deferred 
interventional radiological procedure Diagnosis  of 
BCS was made on CT scan and subsequent Doppler 
ultrasonography 
 
Case Report 
A 24 years old young man presented with progressive 
abdominal distension and shortness of breath for 3 
months. Before onset of these symptoms he had been 
treated for upper abdominal pain and fever that lasted 
for 10 days. He also complained of dry cough, 
anorexia, fatigue, and undocumented weight loss. At 
admission he was pale,had tachycardia (pulse rate 
106/minute), and tachypnea (respiratory rate 
30/minutes). Pedal edema up to ankles and 
lymphadenopathy (bilateral cervical and axillary) 
were noted. Axillary lymph nodes were of 2-3 cm in 
size and were located in central and apical area. 
Cervical lymph nodes were 1.5x1cm in size, and 
located in anterior cervical and supraclavicular 
location. Lymph nodes were soft to firm, discrete, and  
 
mobile. Most were well circumscribed with few 
matted nodes as well. Skin overlying lymph nodes was 
normal. Abdominal examination showed tender 
hepatomegaly (span 16 cm) and moderate ascites. 
Bilateral mild pleural effusions were noted on chest 
examination. Rest of clinical examination was 
unremarkable. All routine investigations were within 
normal limits (Table 1)Pleural and  ascitic fluid  
examination were suggestive of transudate  (Table 2) 
Chest radiograph showed bilateral pleural effusion 
(Figure 1). Ultrasonography showed hepatomegaly, 
ascites, abdominal lymphadenopathy, bilateral pleural 
effusion. Echocardiography was unremarkable .CT 
scans of chest, abdomen, and pelvis were done that 
showed  inhomogeneous enlarged, mottled liver with 
delayed  post contrast enhancement of liver periphery 
and around hepatic veins. The caudate lobe was 
enlarged (caudate lobe hypertrophy) and showed 
increased contrast enhancement compared with the 
remainder of the liver. Hepatic veins were not 
visualized (thrombosed). Marked abdomino-pelvic 
ascites, splenomegaly, collateral formation in 
anterolateral chest wall, bilateral cervical, mediastinal, 
axillary and abdominal lymphadenopathy were also 
noted (Figure 2).Doppler ultrasound also showed 
similar findings. Upper gastrointestinal endoscopy 
showed grade esophageal varices.Biopsy of axillary 
and mediastinal lymph node showed chronic non-
specific lymphadenitis. Bone marrow examination 
revealed reactive changes. Pleural biopsy showed 
chronic inflammatory changes. No definite granuloma 
or feature suggestive of malignancy were noted. 
Diagnosis of idiopathic Budd-Chiari was made. 
Patient was treated with broad spectrum antibiotics, 
analgesics, diuretics, and injectable steroids, in 
addition to anticoagulation. Anti tuberculous therapy 
was also initiated. He deferred interventional 
radiology shunt procedure despite counseling and got 
discharged on request. No remarkable improvement 
was noted on follow up after 1 month.Despite 
repetitive telephonic requests he has not come for 
follow up. 
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Table I. Hematological and biochemical 
investigations 
Investigation Result Investigation Result 
Hemoglobin 8.6 gm% Total 
bilirubin 
0.6 mg% 
MCV 61.4 fL Alanine 
transferase 
(ALT) 
40iu/L 
Peripheral 
film 
Unremark
able 
Alkaline 
phosphatase 
109iu/L 
WBCs 8.3×109/m
m3 
Sreum 
Albumin 
3.2 gm/dl 
Platelets 369×109/
mm3 
Prothrombin 
time (PT) 
WNL* 
ESR 20 mm at 
1 hour 
Activated partial 
thromboplastin 
time (APTT) 
WNL* 
Urea 24 mg% Serum 
Potassium 
3.8mm/L 
Creatinine 0.9 mg% Serum 
Sodium 
138mm/L 
Urine R/E Unremark
able 
Serum Lactic 
dehydrogen
ase (LDH) 
558 iu/L 
ANA Negative Hepatitis B, 
C and HIV 
serology 
Negative 
Anti-
phospholipid
antibody 
Negative Protein C 
and S 
Normal 
RA factor Negative Serum 
Ferritin 
26.73 
ng/mL 
Blood and 
bone marrow 
cultures 
No 
growth 
Brucella 
serology 
Negative 
*WNL; within normal limits 
 
Table  2. Ascitic and pleural fluid analysis 
Ascitic fluid Pleural fluid 
Test Result Test Result 
RBC count 1550cells/µl RBC count 1050cells/µl 
Total leukocyte 
count 
80cells/µl Total leukocyte 
count 
130 cells/µl 
Polymorphs 15% Polymorphs % 10% 
Lymphocytes 85% Lymphocytes % 90% 
Proteins  0.9 g% Proteins 1.3 g% 
Adenosine 
deaminase 
(ADA) 
12 u/l Adenosine 
deaminase(ADA) 
10 u/l 
 
Figure 1. Chest X-Ray showing bilateral pleural effusion 
 
 
 
Figure 2: CT Scan showing mottled liver (arrow) and 
caudate lobe hypertrophy, ascites, and bilateral pleural 
effusion 
 
Discussion 
Gender and age wise differences have been noted in 
BCS patients belonging to Asian and non-Asian 
countries. Asian BCS patients are predominantly male 
and have 45 years median age. Female predominance 
and thirties to forties year age group involvement in 
non-Asian BCS patients has been noted.8Our patient 
was young and male. BCS  can be classified based on 
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site of venous obstruction and clinically. Hepatic veins, 
and inferior venae cavae alone or combined may be 
obstructed in BCS due to thrombosis, external 
compression or webs. Four clinical types of BCS are; 1) 
acute, 2) subacute, 3) chronic, and 4) fulminant.9,10In 
acute type that occurs within weeks, patients have 
painful enlargement of liver. Ascites and upper 
gastrointestinal bleeding due to development of 
varices may occur. Moderate derangement of liver 
enzymes is also noted. In subacute type, patients 
present with progressive ascites that may be 
accompanied by swelling of feet developing in 
months. These patients have minimal derangement of 
liver enzyme. Our patient had sub acute type of BCS. 
Patients with chronic BCS have features of 
decompensated cirrhosis. Patients with fulminant type 
have jaundice, coagulopathy and marked 
derangement of liver enzymes. Hepatic 
encephalopathy develops in these patients within 2 
months of jaundice onset. 
Ascitic fluid protein concenteration in BCS patients is 
generally >2 g% and gradient of serum to ascites 
albumin is <1.1.11Values may be different in acute type 
of BCS. Ultrasongraphy has 85-90% sensitivity and 
specificity for diagnosing BCS when performed by 
triplex method.12 CT scan, magnetic resonance 
imaging, hepatic venography, and liver biopsy are 
further helpful for making diagnosis. Interestingly we 
were thinking of tuberculosis and neoplastic in our 
patient as at presentation he had lymphadenopathy, 
ascites, and pleural effusion. His initial ultrasound also 
showed hepatomegaly, ascites, and abdominal 
lymphadenopathy. Situation changed when we noted 
that ascites and pleural fluid analysis were 
transudative. CT scan findings pointed to the 
diagnosis of BCS. 
Etiological list of BCS is exhaustive. Most patients with 
BCS have underlying thrombotic disorders. In up to 
33% patients etiological diagnosis cannot be made and 
the condition is termed idiopathic. Myeloproliferative 
disorders, malignancy, infections, pregnancy, and 
contraceptive use cause 90% of BCS.13 Our effort in 
this regard remained fruitless, although we started the 
patient on anti-tuberculous therapy empirically. 
Treatment of BCS patients can be divided in to four 
types; 1) treatment of the etiology, 2) conservative, 3) 
surgical, and 4) interventional radiological. 
Conservative treatment includes; managing ascites 
and portal hypertension, anticoagulant therapy, and 
use of thrombolytic agents according to clinical 
scenario. Surgical options include various shunt 
procedures and liver transplantation. Transjugular 
intrahepatic portosystemic shunt (TIPS), 
angioplasty, and stenting are interventional 
radiological options. 
Prognosis in BCS is variable. Patients with unknown 
etiology die in 3-36 months after diagnosis is made. 
Three year survival in these patients is 10%.438-87%, 
five year survival has been noted in patients who are 
treated with various shunting procedures. After liver 
transplant five year survival is 70%.5,6 Outcome in our 
patient is expectedly poor as etiological diagnosis was 
not made and surgical or interventional radiological 
options were deferred by the patient. 
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